Which ICU sedation agent is most associated with delirium risk?

• A. Benzodiazepines (e.g., midazolam)
• B. Propofol
• C. Dexmedetomidine
• D. Ketamine

Answer: (A)

Delirium risk in the ICU is heavily influenced by the sedative chosen. Benzodiazepines, such as midazolam, are most strongly linked to delirium because they amplify GABA-A receptor activity, producing deep, sustained CNS depression. This deep sedation can disrupt brain networks involved in attention, perception, and arousal, and it often leads to prolonged wakefulness desynchrony and sleep-wake cycle disturbances. In turn, patients become more vulnerable to delirium, especially older adults or those with preexisting cognitive impairment, organ dysfunction, or heavy illness burden.

Other agents behave differently. Dexmedetomidine provides sedation with some analgesia and tends to preserve a more natural sleep–like state, which is associated with a lower delirium incidence. Propofol also offers rapid on/off sedation and typically carries less delirium risk than benzodiazepines, though delirium can still occur. Ketamine can cause dissociative experiences and psychomimetic effects, but its delirium risk is not as consistently elevated as with benzodiazepines in many ICU studies.

So, among these options, benzodiazepines are the most associated with delirium risk in the ICU, making them the least favorable choice when delirium prevention is a priority. Practical takeaway: minimize benzodiazepines when possible and favor alternatives like dexmedetomidine or carefully titrated propofol, along with nonpharmacologic delirium prevention strategies.